Skip navigation

Chemical Cyclodecanes

1–50 of 669 results.
  Chemical Phenotype Co-Mentioned Terms Interaction Organisms Anatomy Inference Network References
1. 10-deacetylpaclitaxel negative regulation of cell proliferation 10-deacetylpaclitaxel results in increased negative regulation of cell proliferation 1: Homo sapiens Mammary Glands, Human | Cell Line, Tumor   1
2. 10-deacetylpaclitaxel response to antineoplastic agent Paclitaxel [Paclitaxel results in decreased response to antineoplastic agent] which results in decreased susceptibility to 10-deacetylpaclitaxel 1: Homo sapiens Mammary Glands, Human | Cell Line, Tumor   1
3. 3'-p-hydroxypaclitaxel drug metabolic process Ketoconazole [Ketoconazole results in decreased drug metabolic process] which results in decreased chemical synthesis of 3'-p-hydroxypaclitaxel 1: Homo sapiens Intestine, Large | Microsomes 1 gene: CYP3A4 1
4. 6-hydroxytaxol exogenous drug catabolic process Paclitaxel | Piperonyl Butoxide [[Piperonyl Butoxide results in decreased exogenous drug catabolic process] which results in decreased hydroxylation of Paclitaxel] which results in decreased chemical synthesis of 6-hydroxytaxol 1: Homo sapiens Liver | Microsomes 1 gene: CYP2C8 1
5. 6-hydroxytaxol exogenous drug catabolic process Carbon Monoxide | Paclitaxel [[Carbon Monoxide results in decreased exogenous drug catabolic process] which results in decreased hydroxylation of Paclitaxel] which results in decreased chemical synthesis of 6-hydroxytaxol 1: Homo sapiens Liver | Microsomes 1 gene: CYP2C8 1
6. 6-hydroxytaxol exogenous drug catabolic process Midazolam | Paclitaxel [[Midazolam results in decreased exogenous drug catabolic process] which results in decreased hydroxylation of Paclitaxel] which results in decreased chemical synthesis of 6-hydroxytaxol 1: Homo sapiens Liver | Microsomes 1 gene: CYP2C8 1
7. 6-hydroxytaxol exogenous drug catabolic process Ethinyl Estradiol | Paclitaxel [[Ethinyl Estradiol results in decreased exogenous drug catabolic process] which results in decreased hydroxylation of Paclitaxel] which results in decreased chemical synthesis of 6-hydroxytaxol 1: Homo sapiens Liver | Microsomes 1 gene: CYP2C8 1
8. 6-hydroxytaxol exogenous drug catabolic process Paclitaxel | Quercetin [[Quercetin results in decreased exogenous drug catabolic process] which results in decreased hydroxylation of Paclitaxel] which results in decreased chemical synthesis of 6-hydroxytaxol 1: Homo sapiens Liver | Microsomes 1 gene: CYP2C8 1
9. 6-hydroxytaxol exogenous drug catabolic process Paclitaxel | Verapamil [[Verapamil results in decreased exogenous drug catabolic process] which results in decreased hydroxylation of Paclitaxel] which results in decreased chemical synthesis of 6-hydroxytaxol 1: Homo sapiens Liver | Microsomes 1 gene: CYP2C8 1
10. 6-hydroxytaxol exogenous drug catabolic process Paclitaxel | Testosterone [[Testosterone results in decreased exogenous drug catabolic process] which results in decreased hydroxylation of Paclitaxel] which results in decreased chemical synthesis of 6-hydroxytaxol 1: Homo sapiens Liver | Microsomes 1 gene: CYP2C8 1
11. 6-hydroxytaxol drug metabolic process Ketoconazole [Ketoconazole results in decreased drug metabolic process] which results in decreased chemical synthesis of 6-hydroxytaxol 1: Homo sapiens Intestine, Large | Microsomes 1 gene: CYP2C8 1
12. Docetaxel apoptotic process Cytarabine | fludarabine [fludarabine co-treated with Cytarabine co-treated with Docetaxel] results in increased apoptotic process 1: Homo sapiens Tumor Cells, Cultured
38 genes: AKT1 | BAD | BAK1 | BAX | BCL2 | BCL2L1 | BCL2L11 | BIRC5 | BUB1B | CASP2 | CASP3 | CASP8 | CASP9 | CDK1 | CDKN2A | EPO | FAS | GADD45A | GAPDH | HRAS | IL1B | MAL | MAPK1 | MAPK3 | MCL1 | MCM2 | NCF1 | PARP1 | PRKCB | RAF1 | RB1 | TNF | TNFRSF10A | TNFRSF10B | TNFSF10 | TP53 | TRP53 | XIAP
1
13. Docetaxel apoptotic process Docetaxel results in increased apoptotic process 1: Homo sapiens Tumor Cells, Cultured
38 genes: AKT1 | BAD | BAK1 | BAX | BCL2 | BCL2L1 | BCL2L11 | BIRC5 | BUB1B | CASP2 | CASP3 | CASP8 | CASP9 | CDK1 | CDKN2A | EPO | FAS | GADD45A | GAPDH | HRAS | IL1B | MAL | MAPK1 | MAPK3 | MCL1 | MCM2 | NCF1 | PARP1 | PRKCB | RAF1 | RB1 | TNF | TNFRSF10A | TNFRSF10B | TNFSF10 | TP53 | TRP53 | XIAP
1
14. Docetaxel apoptotic process Cytarabine | fludarabine [Docetaxel co-treated with Cytarabine] promotes the reaction [fludarabine results in increased apoptotic process] 1: Homo sapiens Tumor Cells, Cultured
38 genes: AKT1 | BAD | BAK1 | BAX | BCL2 | BCL2L1 | BCL2L11 | BIRC5 | BUB1B | CASP2 | CASP3 | CASP8 | CASP9 | CDK1 | CDKN2A | EPO | FAS | GADD45A | GAPDH | HRAS | IL1B | MAL | MAPK1 | MAPK3 | MCL1 | MCM2 | NCF1 | PARP1 | PRKCB | RAF1 | RB1 | TNF | TNFRSF10A | TNFRSF10B | TNFSF10 | TP53 | TRP53 | XIAP
1
15. Docetaxel apoptotic DNA fragmentation Cytarabine | fludarabine [fludarabine co-treated with Cytarabine co-treated with Docetaxel] results in increased apoptotic DNA fragmentation 1: Homo sapiens Tumor Cells, Cultured 1 gene: CASP3 1
16. Docetaxel apoptotic process alvocidib [Docetaxel co-treated with alvocidib] results in increased apoptotic process 1: Mus musculus Prostate | Cells
38 genes: AKT1 | BAD | BAK1 | BAX | BCL2 | BCL2L1 | BCL2L11 | BIRC5 | BUB1B | CASP2 | CASP3 | CASP8 | CASP9 | CDK1 | CDKN2A | EPO | FAS | GADD45A | GAPDH | HRAS | IL1B | MAL | MAPK1 | MAPK3 | MCL1 | MCM2 | NCF1 | PARP1 | PRKCB | RAF1 | RB1 | TNF | TNFRSF10A | TNFRSF10B | TNFSF10 | TP53 | TRP53 | XIAP
1
17. Docetaxel apoptotic process Docetaxel results in increased apoptotic process 1: Homo sapiens Pancreas | Cell Line, Tumor
38 genes: AKT1 | BAD | BAK1 | BAX | BCL2 | BCL2L1 | BCL2L11 | BIRC5 | BUB1B | CASP2 | CASP3 | CASP8 | CASP9 | CDK1 | CDKN2A | EPO | FAS | GADD45A | GAPDH | HRAS | IL1B | MAL | MAPK1 | MAPK3 | MCL1 | MCM2 | NCF1 | PARP1 | PRKCB | RAF1 | RB1 | TNF | TNFRSF10A | TNFRSF10B | TNFSF10 | TP53 | TRP53 | XIAP
2
18. Docetaxel apoptotic process Bortezomib Bortezomib inhibits the reaction [Docetaxel results in increased apoptotic process] 1: Homo sapiens Pancreas | Cell Line, Tumor
38 genes: AKT1 | BAD | BAK1 | BAX | BCL2 | BCL2L1 | BCL2L11 | BIRC5 | BUB1B | CASP2 | CASP3 | CASP8 | CASP9 | CDK1 | CDKN2A | EPO | FAS | GADD45A | GAPDH | HRAS | IL1B | MAL | MAPK1 | MAPK3 | MCL1 | MCM2 | NCF1 | PARP1 | PRKCB | RAF1 | RB1 | TNF | TNFRSF10A | TNFRSF10B | TNFSF10 | TP53 | TRP53 | XIAP
1
19. Docetaxel apoptotic process Bortezomib [Bortezomib co-treated with Docetaxel] results in increased apoptotic process 1: Homo sapiens Pancreas | Cell Line, Tumor
38 genes: AKT1 | BAD | BAK1 | BAX | BCL2 | BCL2L1 | BCL2L11 | BIRC5 | BUB1B | CASP2 | CASP3 | CASP8 | CASP9 | CDK1 | CDKN2A | EPO | FAS | GADD45A | GAPDH | HRAS | IL1B | MAL | MAPK1 | MAPK3 | MCL1 | MCM2 | NCF1 | PARP1 | PRKCB | RAF1 | RB1 | TNF | TNFRSF10A | TNFRSF10B | TNFSF10 | TP53 | TRP53 | XIAP
1
20. Docetaxel cell cycle Docetaxel results in increased cell cycle 1: Homo sapiens Pancreas | Cell Line, Tumor
20 genes: BIRC5 | BUB1B | CCNB1 | CDK1 | CDK2 | CDKN1A | CDKN2A | CHFR | GADD45A | H2AFX | KRT18 | MAD2L1 | MAPK1 | MAPK3 | MCM2 | PMP22 | RAD50 | RB1 | TP53 | TRP53
1
21. Docetaxel cell cycle Bortezomib Bortezomib inhibits the reaction [Docetaxel results in increased cell cycle] 1: Homo sapiens Pancreas | Cell Line, Tumor
20 genes: BIRC5 | BUB1B | CCNB1 | CDK1 | CDK2 | CDKN1A | CDKN2A | CHFR | GADD45A | H2AFX | KRT18 | MAD2L1 | MAPK1 | MAPK3 | MCM2 | PMP22 | RAD50 | RB1 | TP53 | TRP53
1
22. Docetaxel cell proliferation Bortezomib Bortezomib promotes the reaction [Docetaxel results in decreased cell proliferation] 1: Homo sapiens Pancreas | Cell Line, Tumor
21 genes: AKT1 | AR | BAD | BAK1 | BAX | BCL2 | BCL2L1 | BUB1B | CDK1 | EGFR | EPO | ERBB2 | FGF2 | HRAS | NCF1 | RAF1 | STAT3 | TNF | TP53 | VEGFA | XRCC5
1
23. Docetaxel cell proliferation Docetaxel results in decreased cell proliferation 1: Homo sapiens Pancreas | Cell Line, Tumor
21 genes: AKT1 | AR | BAD | BAK1 | BAX | BCL2 | BCL2L1 | BUB1B | CDK1 | EGFR | EPO | ERBB2 | FGF2 | HRAS | NCF1 | RAF1 | STAT3 | TNF | TP53 | VEGFA | XRCC5
2
24. Docetaxel cell proliferation Bortezomib Docetaxel promotes the reaction [Bortezomib results in decreased cell proliferation] 1: Homo sapiens Pancreas | Cell Line, Tumor
21 genes: AKT1 | AR | BAD | BAK1 | BAX | BCL2 | BCL2L1 | BUB1B | CDK1 | EGFR | EPO | ERBB2 | FGF2 | HRAS | NCF1 | RAF1 | STAT3 | TNF | TP53 | VEGFA | XRCC5
1
25. Docetaxel apoptotic process Docetaxel results in increased apoptotic process 1: Homo sapiens Pancreas
38 genes: AKT1 | BAD | BAK1 | BAX | BCL2 | BCL2L1 | BCL2L11 | BIRC5 | BUB1B | CASP2 | CASP3 | CASP8 | CASP9 | CDK1 | CDKN2A | EPO | FAS | GADD45A | GAPDH | HRAS | IL1B | MAL | MAPK1 | MAPK3 | MCL1 | MCM2 | NCF1 | PARP1 | PRKCB | RAF1 | RB1 | TNF | TNFRSF10A | TNFRSF10B | TNFSF10 | TP53 | TRP53 | XIAP
1
26. Docetaxel apoptotic process Bortezomib Bortezomib promotes the reaction [Docetaxel results in increased apoptotic process] 1: Homo sapiens Pancreas
38 genes: AKT1 | BAD | BAK1 | BAX | BCL2 | BCL2L1 | BCL2L11 | BIRC5 | BUB1B | CASP2 | CASP3 | CASP8 | CASP9 | CDK1 | CDKN2A | EPO | FAS | GADD45A | GAPDH | HRAS | IL1B | MAL | MAPK1 | MAPK3 | MCL1 | MCM2 | NCF1 | PARP1 | PRKCB | RAF1 | RB1 | TNF | TNFRSF10A | TNFRSF10B | TNFSF10 | TP53 | TRP53 | XIAP
1
27. Docetaxel cell proliferation Docetaxel results in decreased cell proliferation 1: Homo sapiens Pancreas
21 genes: AKT1 | AR | BAD | BAK1 | BAX | BCL2 | BCL2L1 | BUB1B | CDK1 | EGFR | EPO | ERBB2 | FGF2 | HRAS | NCF1 | RAF1 | STAT3 | TNF | TP53 | VEGFA | XRCC5
1
28. Docetaxel cell proliferation Bortezomib Docetaxel promotes the reaction [Bortezomib results in decreased cell proliferation] 1: Homo sapiens Pancreas
21 genes: AKT1 | AR | BAD | BAK1 | BAX | BCL2 | BCL2L1 | BUB1B | CDK1 | EGFR | EPO | ERBB2 | FGF2 | HRAS | NCF1 | RAF1 | STAT3 | TNF | TP53 | VEGFA | XRCC5
1
29. Docetaxel cell cycle Docetaxel results in decreased cell cycle 1: Homo sapiens Prostate | Cell Line, Tumor
20 genes: BIRC5 | BUB1B | CCNB1 | CDK1 | CDK2 | CDKN1A | CDKN2A | CHFR | GADD45A | H2AFX | KRT18 | MAD2L1 | MAPK1 | MAPK3 | MCM2 | PMP22 | RAD50 | RB1 | TP53 | TRP53
4
30. Docetaxel apoptotic process Docetaxel results in increased apoptotic process 1: Homo sapiens Prostate | Cell Line, Tumor
38 genes: AKT1 | BAD | BAK1 | BAX | BCL2 | BCL2L1 | BCL2L11 | BIRC5 | BUB1B | CASP2 | CASP3 | CASP8 | CASP9 | CDK1 | CDKN2A | EPO | FAS | GADD45A | GAPDH | HRAS | IL1B | MAL | MAPK1 | MAPK3 | MCL1 | MCM2 | NCF1 | PARP1 | PRKCB | RAF1 | RB1 | TNF | TNFRSF10A | TNFRSF10B | TNFSF10 | TP53 | TRP53 | XIAP
8
31. Docetaxel apoptotic process Bortezomib Bortezomib inhibits the reaction [Docetaxel results in increased apoptotic process] 1: Homo sapiens Prostate | Cell Line, Tumor
38 genes: AKT1 | BAD | BAK1 | BAX | BCL2 | BCL2L1 | BCL2L11 | BIRC5 | BUB1B | CASP2 | CASP3 | CASP8 | CASP9 | CDK1 | CDKN2A | EPO | FAS | GADD45A | GAPDH | HRAS | IL1B | MAL | MAPK1 | MAPK3 | MCL1 | MCM2 | NCF1 | PARP1 | PRKCB | RAF1 | RB1 | TNF | TNFRSF10A | TNFRSF10B | TNFSF10 | TP53 | TRP53 | XIAP
1
32. Docetaxel cell cycle Bortezomib Bortezomib inhibits the reaction [Docetaxel results in decreased cell cycle] 1: Homo sapiens Prostate | Cell Line, Tumor
20 genes: BIRC5 | BUB1B | CCNB1 | CDK1 | CDK2 | CDKN1A | CDKN2A | CHFR | GADD45A | H2AFX | KRT18 | MAD2L1 | MAPK1 | MAPK3 | MCM2 | PMP22 | RAD50 | RB1 | TP53 | TRP53
1
33. Docetaxel cell proliferation BCL2 [Docetaxel co-treated with BCL2] affects cell proliferation 1: Mus musculus Tumor Cells, Cultured
21 genes: AKT1 | AR | BAD | BAK1 | BAX | BCL2 | BCL2L1 | BUB1B | CDK1 | EGFR | EPO | ERBB2 | FGF2 | HRAS | NCF1 | RAF1 | STAT3 | TNF | TP53 | VEGFA | XRCC5
1
34. Docetaxel apoptotic process BCL2 [Docetaxel co-treated with BCL2] affects apoptotic process 1: Mus musculus Tumor Cells, Cultured
38 genes: AKT1 | BAD | BAK1 | BAX | BCL2 | BCL2L1 | BCL2L11 | BIRC5 | BUB1B | CASP2 | CASP3 | CASP8 | CASP9 | CDK1 | CDKN2A | EPO | FAS | GADD45A | GAPDH | HRAS | IL1B | MAL | MAPK1 | MAPK3 | MCL1 | MCM2 | NCF1 | PARP1 | PRKCB | RAF1 | RB1 | TNF | TNFRSF10A | TNFRSF10B | TNFSF10 | TP53 | TRP53 | XIAP
1
35. Docetaxel apoptotic process Docetaxel results in increased apoptotic process 1: Homo sapiens Lung | Epithelium | Tumor Cells, Cultured
38 genes: AKT1 | BAD | BAK1 | BAX | BCL2 | BCL2L1 | BCL2L11 | BIRC5 | BUB1B | CASP2 | CASP3 | CASP8 | CASP9 | CDK1 | CDKN2A | EPO | FAS | GADD45A | GAPDH | HRAS | IL1B | MAL | MAPK1 | MAPK3 | MCL1 | MCM2 | NCF1 | PARP1 | PRKCB | RAF1 | RB1 | TNF | TNFRSF10A | TNFRSF10B | TNFSF10 | TP53 | TRP53 | XIAP
1
36. Docetaxel cell cycle Docetaxel results in decreased cell cycle 1: Homo sapiens Lung | Epithelium | Tumor Cells, Cultured
20 genes: BIRC5 | BUB1B | CCNB1 | CDK1 | CDK2 | CDKN1A | CDKN2A | CHFR | GADD45A | H2AFX | KRT18 | MAD2L1 | MAPK1 | MAPK3 | MCM2 | PMP22 | RAD50 | RB1 | TP53 | TRP53
1
37. Docetaxel apoptotic DNA fragmentation Docetaxel results in increased apoptotic DNA fragmentation 1: Homo sapiens Lung | Epithelium | Tumor Cells, Cultured 1 gene: CASP3 1
38. Docetaxel cell cycle Docetaxel affects cell cycle 1: Homo sapiens Lung | Cell Line, Tumor
20 genes: BIRC5 | BUB1B | CCNB1 | CDK1 | CDK2 | CDKN1A | CDKN2A | CHFR | GADD45A | H2AFX | KRT18 | MAD2L1 | MAPK1 | MAPK3 | MCM2 | PMP22 | RAD50 | RB1 | TP53 | TRP53
1
39. Docetaxel cell proliferation Docetaxel results in decreased cell proliferation 1: Homo sapiens Lung | Cell Line, Tumor
21 genes: AKT1 | AR | BAD | BAK1 | BAX | BCL2 | BCL2L1 | BUB1B | CDK1 | EGFR | EPO | ERBB2 | FGF2 | HRAS | NCF1 | RAF1 | STAT3 | TNF | TP53 | VEGFA | XRCC5
1
40. Docetaxel cell proliferation sulindac sulfone sulindac sulfone promotes the reaction [Docetaxel results in decreased cell proliferation] 1: Homo sapiens Lung | Cell Line, Tumor
21 genes: AKT1 | AR | BAD | BAK1 | BAX | BCL2 | BCL2L1 | BUB1B | CDK1 | EGFR | EPO | ERBB2 | FGF2 | HRAS | NCF1 | RAF1 | STAT3 | TNF | TP53 | VEGFA | XRCC5
1
41. Docetaxel apoptotic process Docetaxel results in increased apoptotic process 1: Homo sapiens Lung | Cell Line, Tumor
38 genes: AKT1 | BAD | BAK1 | BAX | BCL2 | BCL2L1 | BCL2L11 | BIRC5 | BUB1B | CASP2 | CASP3 | CASP8 | CASP9 | CDK1 | CDKN2A | EPO | FAS | GADD45A | GAPDH | HRAS | IL1B | MAL | MAPK1 | MAPK3 | MCL1 | MCM2 | NCF1 | PARP1 | PRKCB | RAF1 | RB1 | TNF | TNFRSF10A | TNFRSF10B | TNFSF10 | TP53 | TRP53 | XIAP
3
42. Docetaxel apoptotic process sulindac sulfone sulindac sulfone promotes the reaction [Docetaxel results in increased apoptotic process] 1: Homo sapiens Lung | Cell Line, Tumor
38 genes: AKT1 | BAD | BAK1 | BAX | BCL2 | BCL2L1 | BCL2L11 | BIRC5 | BUB1B | CASP2 | CASP3 | CASP8 | CASP9 | CDK1 | CDKN2A | EPO | FAS | GADD45A | GAPDH | HRAS | IL1B | MAL | MAPK1 | MAPK3 | MCL1 | MCM2 | NCF1 | PARP1 | PRKCB | RAF1 | RB1 | TNF | TNFRSF10A | TNFRSF10B | TNFSF10 | TP53 | TRP53 | XIAP
1
43. Docetaxel apoptotic process Docetaxel results in increased apoptotic process 1: Homo sapiens Breast | Cell Line, Tumor
38 genes: AKT1 | BAD | BAK1 | BAX | BCL2 | BCL2L1 | BCL2L11 | BIRC5 | BUB1B | CASP2 | CASP3 | CASP8 | CASP9 | CDK1 | CDKN2A | EPO | FAS | GADD45A | GAPDH | HRAS | IL1B | MAL | MAPK1 | MAPK3 | MCL1 | MCM2 | NCF1 | PARP1 | PRKCB | RAF1 | RB1 | TNF | TNFRSF10A | TNFRSF10B | TNFSF10 | TP53 | TRP53 | XIAP
2
44. Docetaxel cell cycle Docetaxel affects cell cycle 1: Homo sapiens Breast | Cell Line, Tumor
20 genes: BIRC5 | BUB1B | CCNB1 | CDK1 | CDK2 | CDKN1A | CDKN2A | CHFR | GADD45A | H2AFX | KRT18 | MAD2L1 | MAPK1 | MAPK3 | MCM2 | PMP22 | RAD50 | RB1 | TP53 | TRP53
1
45. Docetaxel cell proliferation O-(Chloroacetylcarbamoyl)fumagillol Docetaxel promotes the reaction [O-(Chloroacetylcarbamoyl)fumagillol results in decreased cell proliferation] 1: Homo sapiens Umbilical Cord | Blood Vessels | Endothelium | Cells, Cultured
21 genes: AKT1 | AR | BAD | BAK1 | BAX | BCL2 | BCL2L1 | BUB1B | CDK1 | EGFR | EPO | ERBB2 | FGF2 | HRAS | NCF1 | RAF1 | STAT3 | TNF | TP53 | VEGFA | XRCC5
1
46. Docetaxel cell proliferation O-(Chloroacetylcarbamoyl)fumagillol Docetaxel promotes the reaction [O-(Chloroacetylcarbamoyl)fumagillol results in decreased cell proliferation] 1: Homo sapiens Cell Line, Tumor
21 genes: AKT1 | AR | BAD | BAK1 | BAX | BCL2 | BCL2L1 | BUB1B | CDK1 | EGFR | EPO | ERBB2 | FGF2 | HRAS | NCF1 | RAF1 | STAT3 | TNF | TP53 | VEGFA | XRCC5
1
47. Docetaxel apoptotic process O-(Chloroacetylcarbamoyl)fumagillol Docetaxel promotes the reaction [O-(Chloroacetylcarbamoyl)fumagillol results in increased apoptotic process] 1: Homo sapiens Umbilical Cord | Blood Vessels | Endothelium | Cells, Cultured
38 genes: AKT1 | BAD | BAK1 | BAX | BCL2 | BCL2L1 | BCL2L11 | BIRC5 | BUB1B | CASP2 | CASP3 | CASP8 | CASP9 | CDK1 | CDKN2A | EPO | FAS | GADD45A | GAPDH | HRAS | IL1B | MAL | MAPK1 | MAPK3 | MCL1 | MCM2 | NCF1 | PARP1 | PRKCB | RAF1 | RB1 | TNF | TNFRSF10A | TNFRSF10B | TNFSF10 | TP53 | TRP53 | XIAP
1
48. Docetaxel apoptotic process O-(Chloroacetylcarbamoyl)fumagillol Docetaxel promotes the reaction [O-(Chloroacetylcarbamoyl)fumagillol results in increased apoptotic process] 1: Homo sapiens  
38 genes: AKT1 | BAD | BAK1 | BAX | BCL2 | BCL2L1 | BCL2L11 | BIRC5 | BUB1B | CASP2 | CASP3 | CASP8 | CASP9 | CDK1 | CDKN2A | EPO | FAS | GADD45A | GAPDH | HRAS | IL1B | MAL | MAPK1 | MAPK3 | MCL1 | MCM2 | NCF1 | PARP1 | PRKCB | RAF1 | RB1 | TNF | TNFRSF10A | TNFRSF10B | TNFSF10 | TP53 | TRP53 | XIAP
1
49. Docetaxel apoptotic process 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [Docetaxel results in increased apoptotic process] 1: Homo sapiens Prostate | Cell Line, Tumor
38 genes: AKT1 | BAD | BAK1 | BAX | BCL2 | BCL2L1 | BCL2L11 | BIRC5 | BUB1B | CASP2 | CASP3 | CASP8 | CASP9 | CDK1 | CDKN2A | EPO | FAS | GADD45A | GAPDH | HRAS | IL1B | MAL | MAPK1 | MAPK3 | MCL1 | MCM2 | NCF1 | PARP1 | PRKCB | RAF1 | RB1 | TNF | TNFRSF10A | TNFRSF10B | TNFSF10 | TP53 | TRP53 | XIAP
1
50. Docetaxel cell proliferation Docetaxel results in decreased cell proliferation 1: Homo sapiens Prostate | Cell Line, Tumor
21 genes: AKT1 | AR | BAD | BAK1 | BAX | BCL2 | BCL2L1 | BUB1B | CDK1 | EGFR | EPO | ERBB2 | FGF2 | HRAS | NCF1 | RAF1 | STAT3 | TNF | TP53 | VEGFA | XRCC5
7
1–50 of 669 results.